BOSTON (MarketWatch) - Insmed rocketed while rival Tercica imploded early Tuesday on news that Insmed's drug to treat growth deficiency in children had received U.S. regulatory approval.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.